CN1124143A - 医治受损皮肤的粉末制剂 - Google Patents

医治受损皮肤的粉末制剂 Download PDF

Info

Publication number
CN1124143A
CN1124143A CN95107095A CN95107095A CN1124143A CN 1124143 A CN1124143 A CN 1124143A CN 95107095 A CN95107095 A CN 95107095A CN 95107095 A CN95107095 A CN 95107095A CN 1124143 A CN1124143 A CN 1124143A
Authority
CN
China
Prior art keywords
iodine
powder formulation
polyvinyl pyrrolidone
sucrose
powder preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN95107095A
Other languages
English (en)
Other versions
CN1059088C (zh
Inventor
稻木敏南
末广才备
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Publication of CN1124143A publication Critical patent/CN1124143A/zh
Application granted granted Critical
Publication of CN1059088C publication Critical patent/CN1059088C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

公开了用于医治受损皮肤的粉末制剂，它包括50-90wt.％蔗糖，0.5-10wt.％聚乙烯基吡咯烷酮—碘，和水溶性聚合物，该聚合物选自聚乙烯醇，聚乙烯基吡咯烷酮，聚丙烯酸及其盐类，粗芽短梗孢糖，羧基乙烯基聚合物类，甲基纤维素，羟甲基纤维素，羟丙基甲基纤维素，和羧甲基纤维素及其盐类。该粉末制剂的特征在于，甚至当在运输过程中或者类似情况下振动时或贮存很长时间不会结块，在其使用时不会散落并对伤口表面具有良好的粘合力。

Description

医治受损皮肤的粉末制剂
本发明涉及用于医治受损皮肤，如烧伤或烫伤、褥疮和创伤的外用药剂，更具体地说，涉及用于医治受损的皮肤的粉末制剂，该制剂含有糖和聚乙烯基吡咯烷酮(Povidone)一碘配合物作为活性成份。
糖类如蜂密和糖蜜作为民间传统医药常常用来治疗烧伤或烫伤和创伤。还已知这些糖类具有抑菌作用和粒状组织增生效果。除此之外，聚乙烯基吡咯烷酮—碘在全世界范围内极其广泛地被用作杀菌的药。
最近已有报道，当粒化糖与聚乙烯基吡咯烷酮—碘制剂如聚乙烯吡咯碘酮膏，聚乙烯吡咯碘酮药液或聚烯吡酮碘凝胶(Meiji SeikaKaisha，Ltd.的产品)混合，所得混合物被用于各种受损皮肤时，获得了极好的医治受损皮肤的效果[R.A.Knutson等，“Southern MedicalJournal”，Vol.74，NO.11，1329—1335(1981)；和Kiyokazu Sone等，“Byoin Yakugaku(医院药物学)”，Vol.10，NO.5，315—322(1984)]。
然而，上述组合物存在有关问题：当在室温下贮存时，它们分为两层或者变成淀粉糖浆状，尤其是它们的活性成份分解降低了组合物的药效。因此，它们必须贮存在阴凉避光处。然而，即使以这种方式贮存，活性成份在几个月内会发生分解。刚好在使用它们之前制备该组合物是重要的。
因此，为了克服此类缺点曾经进行了许多研究。结果近年来，已开发出含有蔗糖和聚乙烯基吡咯烷酮—碘作为活性成份以及具有良好的长期贮存稳定性的膏状制剂。此类膏状制剂受到病人的好评和提高了医院的药房效益。但是，具有剧痛或类似症状的病人，则需要开发易于使用的制剂，施用在渗出物很多的伤口表面或很深的伤口，或者施用在易出血的粒状组织的表面。
鉴于以上情况，进行了临床试验，使用了其中将3％的聚乙烯基吡咯烷酮—碘粉末引入蔗糖的粉末制剂[“Nichiidai—shi(Journal ofNippon Medical.College)”，Vol.57，NO.2，94(1990)]。但是，这种粉末制剂存在缺点，在长时间的贮存过程中，它会出现结块现象，或者由于占粉末制剂97％的蔗糖的固有性质的缘故，由其运输过程中的振动而发生结块现象，因此，它既不能从容器中取出也不能散开使用。
因此，本发明的目的是提供一种粉末制剂，该制剂含有蔗糖和聚乙聚基吡咯烷酮—碘并且甚至贮存很长时间时，不会结块。
鉴于以上情况，本发明人已进行了深入的研究。结果，已经发现，当一种特定的水溶性聚合物引入蔗糖和聚乙烯基吡咯烷酮—碘中时，可以获得一种粉末制剂，该制剂甚至贮存长时间也不会结块的，表现出对伤口表面极好的粘合性，因为通过把它散布在纱布上或者类似物上并加压而被结合成块的缘故在使用时不会散落，尤其可以通过水洗方便地除去，因此而完成了本发明。
在本发明的一个方面，提供了一种用于医治受损皮肤的粉末制剂，它包括(a)50—90wt.％蔗糖，(b)0.5—10wt％聚乙烯基吡咯烷酮—碘，和(c)一种水溶性聚合物，该聚合物选自聚乙烯醇，聚乙烯基吡咯烷酮，聚丙烯酸及其盐类，出芽短梗孢糖，羧基乙烯基聚合物类，甲基纤维素，羟甲基纤维素，羟丙基甲基纤维素，和羧甲基纤维素及其盐类。
根据本发明的用于医治受损皮肤的粉末制剂，甚至当在运输过程中或者在类似情况下振动时或者贮存很长时间都不会发生结块，尤其是，它被装在振荡器中使用时具有良好的效果，在其使用过程中不会散落和对伤口表面具有良好的粘附力。
本发明的以上和其它目的、特征和优点从以下叙述和所附的权利要求中来看，将会变得很清楚。
在本发明中，为了获得均匀质量的组合物，在日本药典或者类似书籍上说明的蔗糖或者纯化蔗糖被用作蔗糖(a)则是特别优选的。另一方面，在日本药典或者类似书籍上描述的聚乙烯基吡咯烷酮—碘配合物被用作聚乙烯基吡咯烷酮—碘(b)。
被引入的蔗糖(a)的量是整个组合物的50—90wt.％(下文仅仅由“％”表示)，优选60—80％。被引入的聚乙烯基吡咯烷酮—碘(b)的量落在0.5％(表现出杀菌作用所需要的最低比例)至10％的范围内。
在本发明中，水溶性聚合物(c)使由蔗糖和聚乙烯基吡咯烷酮—碘组成的制剂具有特定的效果，如粘合性，防止散落和防止结块。此类水溶性聚合物既可以单个使用又可以以两种或多种聚合物的结合物的形式使用，并以整个组合物的1—40％的比例引入，优选4—20％。
特别优选的水溶性聚合物的例子包括羧基乙烯基聚合物类和羧甲基纤维素钠。
除了这些必要的成份之外，根据需要，可以向根据本发明的制剂中引入常用的赋形剂，例如，糖醇(d)如甘露糖醇，麦芽糖醇，木糖醇或山梨糖醇。
如果被引入的话，糖醇(d)的量优选占整个组合物的10—30％，尤其是15—25％。
对根据本发明制剂的制备方法没有特别的限制。例如，通过由高速粉磨机或类似设备将蔗糖和赋形剂如糖醇一起磨成细粉，向这细粉中添加聚乙烯基吡咯烷酮—碘和水溶性聚合物，及由双缸混合机或类似的设备均匀混合所得混合物面制备该制剂。如果需要，由此制得的粉末制剂可以进行定级。
通过以下实例，将在下文中更详细地描述本发明。
实施例一
                             (重量份数)(1)聚乙烯基吡咯烷酮—碘           3(2)纯化蔗糖                       70(3)羧甲基纤维素钠                 20(4)羧基乙烯基聚合物               7
在成份(2)的粒径由高速粉磨机调节好后，成份(1)，(3)和(4)被加入到其中，在混合器中将所得混合物均匀地混合成粉末制剂。
这种粉末制剂甚至在50℃下贮存一个月后仍然表现出均匀的粉末状态。
实施例二
按照与实施例一中同样的方式配制具有表1所示相应组成的粉末制剂，在50℃下一个月以后观察它们的性能。结果示于表1。
表1
成分(％) 发明产物1 发明产物2 发明产物3 发明产物4 发明产物5 发明产物6 对比产物1 对比产物2
聚乙烯基吡咯烷酮—碘蔗糖甘露糖醇CMC-MaCVPPVPPVA     77018---5     390--7--     1.55033.515---    560305---     37020.551.5--     3807--10-    397-----    37027----
性质  粉末状  粉末状  粉末状  粉末状   粉末状  粉末状   结块   结块
注：CMC-Na：羧甲基纤维素钠
    CVP：   羧基乙烯基聚合物
    PVP：   聚乙烯基吡咯烷酮
    PVA：   聚乙烯醇
实施例三
按照与实施例一中同样的方式配制具有表2所示相应组成的粉末制剂，在50℃下贮存一个月之后观察其性质和外观。结果示于表2。
表2
     成分(％) 发明产物1 发明产物2 对比产物3 对比产物4 对比产物5
聚乙烯基吡咯烷酮—碘蔗糖甘露糖醇PVACVPPluronic F68脂肪酸蔗糖酯聚乙二醇6000     770185----     390--7---     387---10--     387----10-     387-----10
性质外观   粉末状未变化   粉末状未变化    结块变黑  结块末变化 结块变黄
注：PVA：聚乙烯醇
    CVP：羧基乙烯基聚合物
    Pluronic F68：聚氧乙烯〔160〕聚氧丙烯〔30〕二醇

Claims (4)

1.用于医治受损皮肤的粉末制剂，它包括：
(a)50—90wt.％蔗糖
(b)0.5—10wt.％聚乙烯基吡咯烷酮—碘；和
(c)水溶性聚合物，选自聚乙烯醇，聚乙烯基吡咯烷酮，聚丙烯酸及其盐类，出芽短梗孢糖，羧基乙烯基聚合物类，甲基纤维素，羟甲基纤维素，羟丙基甲基纤维素，和羧甲基纤维素及其盐类。
2.根据权利要求1的粉末制剂，其中含有占整个组合物的1—40wt.％的量的水溶性聚合物(c)。
3.根据权利要求1的粉末制剂，还包括(d)糖醇。
4.根据权利要求3的粉末制剂，其中含有占整个组合物的10—30％的量的糖醇。
CN95107095A 1994-06-27 1995-06-26 医治受损皮肤的粉末制剂 Expired - Fee Related CN1059088C (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP144393/94 1994-06-27
JP144393/1994 1994-06-27
JP14439394A JP3583166B2 (ja) 1994-06-27 1994-06-27 損傷皮膚修復用粉末製剤

Publications (2)

Publication Number Publication Date
CN1124143A true CN1124143A (zh) 1996-06-12
CN1059088C CN1059088C (zh) 2000-12-06

Family

ID=15361113

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95107095A Expired - Fee Related CN1059088C (zh) 1994-06-27 1995-06-26 医治受损皮肤的粉末制剂

Country Status (12)

Country Link
US (1) US5618799A (zh)
EP (1) EP0689841B1 (zh)
JP (1) JP3583166B2 (zh)
KR (1) KR100370313B1 (zh)
CN (1) CN1059088C (zh)
AT (1) ATE230270T1 (zh)
CA (1) CA2150888A1 (zh)
DE (1) DE69529249T2 (zh)
DK (1) DK0689841T3 (zh)
ES (1) ES2189811T3 (zh)
SI (1) SI0689841T1 (zh)
TW (1) TW336173B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026928A1 (fr) * 2004-09-09 2006-03-16 Yiming Lv Vulneraire et procede de fabrication et d'utilisation associe
CN101654499B (zh) * 2009-09-02 2011-08-31 陈煜� 天然高分子或其水溶性衍生物的两亲性接枝共聚物与纳米碘复合物及其制备方法

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU722246B2 (en) * 1995-06-07 2000-07-27 Johnson & Johnson Consumer Products, Inc. Stable complexes of crosslinked polyvinylpyrrolidone and iodine and method of making the same
US6562885B1 (en) 1998-03-19 2003-05-13 Battelle Memorial Institute Composition for deactivating chemically and biologically active agents and method of making the same
DE69910210T2 (de) 1998-06-19 2004-06-17 Oxibio, Inc., Portland Implantierbare medizinische vorrichtung mit antiinfektiösen und kontrazeptiven eigenschaften
US6414223B1 (en) * 1998-08-03 2002-07-02 Cargill, Incorporated Plants, seeds and oils having an elevated total monounsaturated fatty acid content
AU753292B2 (en) 1999-02-26 2002-10-17 Warner-Lambert Company Llc Bioadhesive antibacterial wound healing composition
JP2001122790A (ja) * 1999-10-22 2001-05-08 Mikasa Seiyaku Co Ltd 安定な褥瘡・皮膚潰瘍および創傷治療用製剤
CN1272071C (zh) 2002-03-14 2006-08-30 美德阿利克斯株式会社 创伤用外用剂
WO2004011032A1 (ja) * 2002-07-26 2004-02-05 Mikasa Seiyaku Co., Ltd. 外用剤
KR101056410B1 (ko) * 2002-11-11 2011-08-11 테이카 세이야쿠 가부시키가이샤 손상 피부 회복용 조성물
US20040101507A1 (en) * 2002-11-27 2004-05-27 Janco Predovan Skin cream
AU2003293818A1 (en) * 2002-12-19 2004-07-14 Gunther Beisel Method for producing agents which are to be administered orally and corresponding compositions using polymers and coatings thereof consisting of hydrophilic liquids
RU2245723C1 (ru) * 2003-07-24 2005-02-10 Вилесов Александр Дмитриевич Средство и способ лечения гнойно-воспалительных заболеваний мягких тканей
WO2005027940A1 (ja) * 2003-09-22 2005-03-31 Kowa Co., Ltd. 損傷皮膚修復用貼付剤
US7673841B2 (en) 2004-03-25 2010-03-09 Cooper Technologies Company Hangar bar for recessed luminaires with integral nail
JP4575706B2 (ja) * 2004-04-23 2010-11-04 興和株式会社 損傷皮膚修復用組成物
JP4575705B2 (ja) * 2004-04-23 2010-11-04 興和株式会社 損傷皮膚修復用組成物
US7334538B1 (en) * 2004-07-27 2008-02-26 Aquascience Research Group, Inc. Topical medicants for aquatic animals
SI1878426T1 (sl) 2005-04-26 2010-09-30 Dainippon Sumitomo Pharma Co Granulatni pripravek ki vsebuje bigvanidno spojino
NZ542258A (en) * 2005-09-06 2010-05-28 Comvita New Zealand Ltd A medical composition comprising honey or sugar syrup and a viscosity increasing agent for use on wounds
WO2007049952A1 (en) * 2005-10-28 2007-05-03 Nature Products Holding B.V. Polymeric compound, method of preparing a polymeric compound, use of a polymeric compound
WO2008050847A1 (fr) 2006-10-25 2008-05-02 Dainippon Sumitomo Pharma Co., Ltd. Préparation granulaire non agglutinante
JP5289975B2 (ja) * 2006-12-07 2013-09-11 第一三共株式会社 マンニトール又は乳糖を含有する固形製剤
CN101594865A (zh) 2006-12-07 2009-12-02 第一三共株式会社 含有低取代的羟基丙基纤维素的药物组合物
BRPI0719398A2 (pt) * 2006-12-07 2015-03-31 Daiichi Sankyo Company Ltd E Ube Ind Ltd Composição farmacêutica.
EP2100606A4 (en) * 2006-12-07 2009-12-30 Daiichi Sankyo Co Ltd COATED PREPARATION OF A FILM HAVING IMPROVED STABILITY
US8071713B2 (en) * 2008-09-22 2011-12-06 Triomed Innovations Corp. Iodinated resin manufacturing process and product
CN102846776B (zh) * 2012-09-28 2015-02-11 刘艳 一种由桃树末制成的药剂
JP2018500312A (ja) * 2014-12-30 2018-01-11 スリーエム イノベイティブ プロパティズ カンパニー 消毒組成物
MX2017009450A (es) * 2015-01-20 2018-01-18 Veloce Biopharma Llc Composicion yodofora novedosa y metodos de uso.
EP4340848A1 (en) * 2021-05-18 2024-03-27 Povinez LLC Nasal antiseptic

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2353297A1 (fr) * 1976-01-26 1977-12-30 Tissier Gerard Nouveaux complexes neutres et insolubles de la polyvinylpolypyrrolidone et des halogenes, leurs procedes d'obtention et leurs applications
US4094967A (en) * 1976-10-22 1978-06-13 Allor Foundation Iodine-polyvinylpyrrolidone solid product and method of preparation
AU536885B2 (en) * 1979-04-18 1984-05-31 R. A. Knutson Wound and burn dressing
DE3312431A1 (de) * 1983-04-07 1984-10-11 B. Braun Melsungen Ag, 3508 Melsungen Pvp-iod-wundpuder mit synergistisch wirkender pudergrundlage
NL8500774A (nl) * 1985-03-18 1986-10-16 Dagra Nv Werkwijze ter bereiding van een vrij vloeiend, homogeen povidonjood wondpoeder.
CA1287584C (en) * 1986-09-02 1991-08-13 Seiichi Komori Wound-healing preparations
GB8622012D0 (en) * 1986-09-12 1986-10-22 Euro Celtique Sa Solid iodophor composition
CH678697A5 (zh) * 1989-04-03 1991-10-31 Warner Lambert Co
US4877927A (en) * 1989-04-06 1989-10-31 Hamlin Incorporated Extended dwell shock sensing device

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026928A1 (fr) * 2004-09-09 2006-03-16 Yiming Lv Vulneraire et procede de fabrication et d'utilisation associe
CN101654499B (zh) * 2009-09-02 2011-08-31 陈煜� 天然高分子或其水溶性衍生物的两亲性接枝共聚物与纳米碘复合物及其制备方法

Also Published As

Publication number Publication date
ATE230270T1 (de) 2003-01-15
ES2189811T3 (es) 2003-07-16
TW336173B (en) 1998-07-11
DE69529249T2 (de) 2003-08-07
JPH0812582A (ja) 1996-01-16
US5618799A (en) 1997-04-08
SI0689841T1 (en) 2003-04-30
KR960000214A (ko) 1996-01-25
KR100370313B1 (ko) 2003-03-19
CA2150888A1 (en) 1995-12-28
JP3583166B2 (ja) 2004-10-27
EP0689841B1 (en) 2003-01-02
CN1059088C (zh) 2000-12-06
DE69529249D1 (de) 2003-02-06
DK0689841T3 (da) 2003-02-24
EP0689841A1 (en) 1996-01-03

Similar Documents

Publication Publication Date Title
CN1059088C (zh) 医治受损皮肤的粉末制剂
DE60320652T2 (de) Zusammensetzung frei von ascorbicsäure enthaltend einen hemmer der cholesterinabsorption, einen hemmer der hmg-coa reduktase und ein stabilisierungsmittel
JP5259030B2 (ja) 薬物を含有する化合物の制御放出用の無機物−ポリマー複合体
DE69434640T2 (de) Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe
US5211958A (en) Pharmaceutical composition and process for its preparation
ES2684325T3 (es) Proceso y formulación de compresión directa
DE69838300T2 (de) Pharmazeutische suspensionstabletten-zusammenstellungen
CN1475207B (zh) 含瓦尔沙登和氢氯噻嗪的固体口服剂量形式
DE60103299T2 (de) Schnell zerfallende cefuroxim axetil enthaltende arzneizusammensetzung mit verzögerter wirkstoffabgabe
EP3174530B1 (de) Direkt verpressbare polyvinylalkohole
AT5350U1 (de) Medikament zur oralen verabreichung
EA001537B1 (ru) Гранулят для получения быстрораспадающихся и быстрорастворяющихся композиций, содержащих большое количество лекарственного средства
EP3174531A1 (de) Direkt verpressbare zusammensetzung enthaltend mikrokristalline cellulose
CA1288333C (en) Solid iodophor composition
JP4293572B2 (ja) ロキソプロフェン・ナトリウム含有錠剤
CN1031862C (zh) 药物组合物及其制备方法
CN1039673C (zh) 阿糖胞苷十八烷基磷酸盐硬胶囊
WO2005117899A1 (en) Pharmaceutical composition comprising tibolone and process for procuding the same
JPS6310731A (ja) 安定な損傷皮膚修復用製剤
JP2953649B2 (ja) 皮膚潰瘍用外用散剤
DE602004007302T2 (de) Verfahren zur herstellung von komprimierten festen dosierungsformen, das gut zur verwendung mit schlecht wasserlöslichen arzneistoffen geeignet ist, und danach hergestellte komprimierte feste dosierungsformen
JP4370050B2 (ja) クラリスロマイシン錠剤およびその製造法
DE60309356T2 (de) Zusammensetzung, durch zusammen vermahlen eines wirkstoffes mit einem n-vinyl-2-pyrrolidon/vinylacetatkopolymers erhältlich
CN1515262A (zh) 阿德福韦酯肠溶制剂
JP2516542B2 (ja) 乳酸菌含有瀉下薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee